Skip to main content
main-content

Rheumatology

Latest articles

08-06-2020 | Rheumatology | News | Article

Methotrexate unlikely to exacerbate risk for ILD in RA patients

Methotrexate treatment does not contribute to the increased risk for interstitial lung disease observed among patients with rheumatoid arthritis, according to data from a Danish cohort study presented at the EULAR 2020 E-congress.

08-06-2020 | Rheumatology | News | Article

Sustained benefits with secukinumab in nonradiographic axial spondyloarthritis

The IL-17A inhibitor secukinumab provides significant and sustained improvements in patients with nonradiographic axial spondyloarthritis, indicate 52-week data from the phase 3 PREVENT study.

08-06-2020 | Rheumatology | News | Article

No benefit of therapeutic drug monitoring in patients starting infliximab therapy

Study results presented at the EULAR 2020 E-Congress suggest that implementing an individualized therapeutic drug monitoring strategy at the time of infliximab initiation does not improve remission rates in patients with a range of inflammatory diseases.

08-06-2020 | Rheumatology | News | Article

Upadacitinib outperforms abatacept in head-to-head RA trial

The JAK1 selective inhibitor upadacitinib improves disease activity to a greater degree than abatacept in rheumatoid arthritis patients with previous biologic exposure, show data presented at the EULAR 2020 E-Congress.

07-06-2020 | Rheumatology | News | Article

EULAR issues provisional COVID-19 recommendations

EULAR has released provisional recommendations for the management of rheumatic diseases during the COVID-19 pandemic.

06-06-2020 | Rheumatology | News | Article

COVID-19 hospitalization: What do the data tell us?

There were a variety of sessions at the EULAR 2020 E-Congress talking about the risk factors associated with COVID-19 hospitalization among patients with rheumatic conditions, as data from the COVID-19 Global Rheumatology Alliance registry and contributing national registries become available.

06-06-2020 | Rheumatology | News | Article

Anakinra ‘an additional option’ to treat flares in difficult-to-treat gout

Phase 2 study anaGO findings presented in a poster at the EULAR 2020 E-congress reveal that patients with difficult-to-treat gout who receive the interleukin-1 receptor antagonist anakinra report comparable levels of pain reduction to those given triamcinolone.

06-06-2020 | Rheumatology | News | Article

No benefit of hydroxychloroquine for inflammatory, erosive hand osteoarthritis

The OA TREAT investigators have demonstrated that hydroxychloroquine does not improve pain, function, or radiographic progression in patients with inflammatory and erosive hand osteoarthritis.

06-06-2020 | Rheumatology | News | Article

Etanercept linked to elevated risk for anterior uveitis in patients with SpA

Etanercept is associated with a higher risk for anterior uveitis than adalimumab among patients with spondyloarthritis, suggests a Swedish registry study.

05-06-2020 | Rheumatology | News | Article

JAKPOT study takes a real-world look at JAK inhibitor retention vs TNF inhibitor

Real-world data from the JAKPOT study suggest slightly higher retention with JAK inhibitors than TNF inhibitors in patients with rheumatoid arthritis, but not significantly so due to rates varying widely from country to country.

05-06-2020 | Rheumatology | News | Article

Adding csDMARD improves TNF inhibitor retention in axSPA

Axial spondyloarthritis patients may be less likely to stop taking TNF inhibitor treatment if they receive it in combination with a conventional synthetic DMARD, EuroSpA registry findings show.

05-06-2020 | Rheumatology | News | Article

Upadacitinib shows promise for PsA

The SELECT-PsA-1 and SELECT-PsA-2 trials presented at the EULAR 2020 E-Congress have demonstrated that upadacitinib may be a promising treatment option for psoriatic arthritis patients with and without prior exposure to biologic agents.

05-06-2020 | Rheumatology | News | Article

Belimumab shows promise for lupus nephritis

Adding belimumab to standard therapy improves renal outcomes among patients with lupus nephritis, indicate findings from the BLISS-LN trial presented at the EULAR 2020 E-Congress.

05-06-2020 | Rheumatology | News | Article

Phase 3 results ADVOCATE C5a receptor inhibition for ANCA-associated vasculitis

Findings from the ADVOCATE trial suggest that patients with antineutrophil cytoplasmic antibody-associated vasculitis who are treated with avacopan are more likely to experience sustained remission than those given glucocorticoids.

05-06-2020 | Rheumatology | News | Article

RE-EMBARK study sheds light on etanercept tapering in patients with nonradiographic axSpA

Temporary discontinuation of etanercept could be an option for around a quarter of patients with nonradiographic axial spondyloarthritis who achieve stable inactive disease, delegates were told at the EULAR 2020 E-Congress.

04-06-2020 | Rheumatology | News | Article

VTE risk linked to high disease activity in RA

Rheumatoid arthritis disease activity is strongly associated with the risk for venous thromboembolism, show results from a Swedish cohort study.

04-06-2020 | Rheumatology | News | Article

​​​​​​​TNF inhibitors linked to reduced VTE risk in RA patients

Patients with rheumatoid arthritis who are treated with TNF inhibitors have a significantly lower risk for venous thromboembolism than those given conventional DMARDs, suggests an analysis of the German RABBIT registry.

04-06-2020 | Rheumatology | News | Article

Sustained response to secukinumab for PsA patients with axial manifestations

Secukinumab provides sustained improvement in clinical and imaging outcomes in patients with psoriatic arthritis and axial manifestations who have had an inadequate response to nonsteroidal anti-inflammatory drugs, show 52-week data from the MAXIMISE trial.

04-06-2020 | Rheumatology | News | Article

Structural entheseal lesions may predict PsA progression risk in patients with psoriasis

Patients with psoriasis who have structural entheseal lesions and cortical bone loss at entheseal segments are at increased risk for progressing to psoriatic arthritis, research suggests.

04-06-2020 | Rheumatology | News | Article

ARCTIC REWIND supports TNF inhibitor continuation in sustained RA remission

Withdrawal of tumor necrosis factor inhibitors leads to a “steep increase” in flare risk among patients with rheumatoid arthritis (RA) in longstanding remission, report the ARCTIC REWIND investigators.